In an ever-evolving healthcare landscape, clinical research remains the backbone of medical advancements. Yet, challenges persist, notably in patient recruitment and engagement. Addressing these issues head-on, Avallano, a leader in data privacy and healthcare technology, has partnered with Elligo Health Research®, the largest healthcare-enabling research organization. Together, they're reshaping the face of clinical trials with the launch of myTrialsConnectSM.
A Bold Step Forward in Clinical Trials
myTrialsConnectSM stands as a testament to the potential of artificial intelligence (AI) in clinical research. Engineered to be patient-first, this AI-powered platform focuses on two pivotal aspects: finding qualified patients and maintaining their engagement before, during, and after studies. It's an all-in-one solution, serving not only patients but also providers, sites, and the biopharma industry.
What Sets myTrialsConnectSM Apart?
Avallano’s commitment to harnessing the power of data privacy and technology shines through in myTrialsConnectSM:
For Patients: Beyond mere participation, patients receive a copy of their full medical record, tailored educational materials, and customized messages. They're continuously informed about clinical trials they're eligible for, through automated medical record reviews and intuitive chatbot surveys.
For Providers: A holistic view of patients’ medical history is no longer a wish. With myTrialsConnectSM, providers gain insights into the entirety of a patient's medical journey. An open communication channel, customizable to individual patient populations, facilitates this deeper understanding.
For Biopharma: The biopharmaceutical industry often grapples with delays in patient recruitment. myTrialsConnectSM alleviates this by creating a virtual waiting room. Patients pre-qualified via medical records and additional data express their study interests, optimizing the recruitment process.
Avallano's Role in the Revolution
Under the visionary leadership of CEO and CTO Paul Della Maggiora, Avallano has been instrumental in the realization of myTrialsConnectSM. With a focus on gleaning precise real-world data and leveraging AI's predictive capabilities, Avallano has ensured that the platform streamlines trial processes.
Paul Della Maggiora remarks, “This patient-first ecosystem has the power to redefine outcomes in clinical research, offering deeper insights, reducing recruitment time, and building patient trust through engagement.”
Indeed, with myTrialsConnectSM, Avallano is not merely offering a solution. They're offering a paradigm shift in how clinical research is perceived, conducted, and benefited from.
In Conclusion
The partnership between Avallano and Elligo Health Research® signals a promising horizon for clinical research. With myTrialsConnectSM, they're demonstrating how technology, when aligned with patient needs and industry demands, can lead to transformative solutions. As clinical research continues to evolve, Avallano remains at the forefront, ushering in an era of data-driven, patient-centric advancements.
For more on Avallano’s AI-enabled clinical research journey, visit Avallano’s Website.